Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | APEX1 | P27695 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | TST | Q16762 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34972 | 0.87 | TERT (0.76) | TERTAPPBRD4ALOX15KDM4E | |
| SCHEMBL31682973 | 0.87 | TERT (0.76) | TERTAPPBRD4ALOX15KDM4E | |
| SCHEMBL6616091 | 0.83 | TERT (1.00) | TERTAPPBRD4ALOX15KDM4E | |
| SCHEMBL31682991 | 0.80 | APP (1.00) | TERTAPPALOX15KDM4EMEN1 | |
| SCHEMBL35096 | 0.80 | APP (1.00) | TERTAPPALOX15KDM4EMEN1 | |
| SCHEMBL6803457 | 0.80 | TERT (1.00) | TERTAPPBRD4ALOX15KDM4E | |
| SCHEMBL12639988 | 0.76 | MEN1 (0.61) | TERTAPPBRD4ALOX15KDM4E | |
| SCHEMBL7655891 | 0.73 | APP (0.67) | TERTAPPALOX15KDM4EMEN1 | |
| SCHEMBL34929 | 0.73 | APP (0.67) | TERTAPPALOX15KDM4EMEN1 | |
| SCHEMBL29904505 | 0.73 | FBP1 (0.61) | TERTAPPALOX15KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-01 | — | — | US | claimed |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2002-10-31 | — | — | US | claimed |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| EP-1373244-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-02 | — | — | EP | disclosed |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
| WO-2002074036-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | TERT 1/4885APP 2705/4885BRD4 46/4885 |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | TERT 1/4885APP 2710/4885BRD4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.